Please enable JavaScript to continue using this application.

Compare $PLX vs $RNAC | Chartloom

Compare

$PLX vs $RNAC

Protalix Biotherapeutics Inc · Cartesian Therapeutics Inc

PLX

Protalix Biotherapeutics Inc

RNAC

Cartesian Therapeutics Inc

Compare $PLX vs $RNAC

Comparing Protalix Biotherapeutics Inc and Cartesian Therapeutics Inc

PLXProtalix Biotherapeutics Inc

RNACCartesian Therapeutics Inc

PLXProtalix Biotherapeutics Inc

Market cap

$224M

P/E (TTM)

12.11x

Forward P/E (NTM)

—

Forward P/S (NTM)

3.56x

Rev growth (TTM)

30.1%

YTD performance

59.8%

52W performance

8.2%

FCF yield

3.4%

RNACCartesian Therapeutics Inc

Market cap

$207M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

473.62x

Rev growth (TTM)

-20.7%

YTD performance

4.4%

52W performance

-31.0%

FCF yield

-37.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

PLX

RNAC

Detailed metrics comparison

PLX

Protalix Biotherapeutics Inc

RNAC

Cartesian Therapeutics Inc

Market Cap

PLX$224M

RNAC$207M

Enterprise Value

PLX$197M

RNAC$113M

Price

PLX$2.78

RNAC$7.06

P/E Ratio

PLX12.11x

RNACN/A

P/S Ratio

PLX2.78x

RNAC140.34x

EV/Sales

PLX2.44x

RNAC76.18x

EV/EBITDA

PLX7.37x

RNAC0.00x

P/B Ratio

PLX3.06x

RNAC296.12x

P/FCF Ratio

PLX29.21x

RNACN/A

EV/FCF

PLX25.63x

RNAC-1.43x

PEG Ratio

PLX0.06x

RNACN/A

Forward P/E (NTM)

PLXN/A

RNACN/A

Forward P/S (NTM)

PLX3.56x

RNAC473.62x

Revenue (TTM)

PLX$81M

RNAC$1M

Revenue Growth (YoY)

PLX30.1%

RNAC-20.7%

Forward Rev Growth

PLX-19.1%

RNAC-14.0%

Gross Margin (TTM)

PLX69.2%

RNAC0.0%

Operating Margin (TTM)

PLX28.9%

RNAC0.0%

EBITDA Margin (TTM)

PLX30.8%

RNAC-6503.1%

Net Margin (TTM)

PLX23.5%

RNAC-10422.5%

FCF Margin (TTM)

PLX9.5%

RNAC-5322.4%

Net Income (TTM)

PLX$19M

RNAC$-154M

FCF (TTM)

PLX$8M

RNAC$-79M

EPS (TTM)

PLX$0.23

RNAC-$5.16

ROE (TTM)

PLX31.6%

RNAC-321582.0%

ROA (TTM)

PLX20.1%

RNAC-4761.0%

ROIC (TTM)

PLX31.6%

RNAC-321582.0%

Cash

PLX$27M

RNAC$148M

Debt

PLX$0

RNAC$53M

Net Cash/Debt

PLX$27M

RNAC$95M

Current Ratio (TTM)

PLX2.94x

RNAC7.48x

Quick Ratio (TTM)

PLX1.91x

RNAC7.19x

Debt/Equity (TTM)

PLX0.00x

RNAC0.28x

Debt/Assets (TTM)

PLX0.0%

RNAC0.0%

Interest Coverage (TTM)

PLXN/A

RNACN/A

Net Debt/EBITDA (TTM)

PLX0.00x

RNAC0.00x

Beta

PLX-0.05

RNAC0.74

52W Performance

PLX8.2%

RNAC-31.0%

YTD Performance

PLX59.8%

RNAC4.4%

% from 52W High

PLX-12.9%

RNAC-35.9%

% from 52W Low

PLX73.7%

RNAC26.0%

Asset Turnover (TTM)

PLX0.85x

RNAC0.01x

FCF Yield (TTM)

PLX3.4%

RNAC-37.9%

Earnings Yield (TTM)

PLX8.5%

RNAC-74.3%

Dividend Yield (TTM)

PLXN/A

RNACN/A

Rule of 40

PLX39.7

RNAC-5,343.1

EV/GP/RG

PLXN/A

RNACN/A

Ticker research

View PLX research View RNAC research

Metric	PLX Protalix Biotherapeutics Inc	RNAC Cartesian Therapeutics Inc
Market & Valuation
Market Cap	$224M	$207M
Enterprise Value	$197M	$113M
Price	$2.78	$7.06
P/E Ratio	12.11x	N/A
P/S Ratio	2.78x	140.34x
EV/Sales	2.44x	76.18x
EV/EBITDA	7.37x	0.00x
P/B Ratio	3.06x	296.12x
P/FCF Ratio	29.21x	N/A
EV/FCF	25.63x	-1.43x
PEG Ratio	0.06x	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.56x	473.62x
Revenue & Growth
Revenue (TTM)	$81M	$1M
Revenue Growth (YoY)	30.1%	-20.7%
Forward Rev Growth	-19.1%	-14.0%
Profitability
Gross Margin (TTM)	69.2%	0.0%
Operating Margin (TTM)	28.9%	0.0%
EBITDA Margin (TTM)	30.8%	-6503.1%
Net Margin (TTM)	23.5%	-10422.5%
FCF Margin (TTM)	9.5%	-5322.4%
Net Income (TTM)	$19M	$-154M
FCF (TTM)	$8M	$-79M
EPS (TTM)	$0.23	-$5.16
ROE (TTM)	31.6%	-321582.0%
ROA (TTM)	20.1%	-4761.0%
ROIC (TTM)	31.6%	-321582.0%
Financial Health
Cash	$27M	$148M
Debt	$0	$53M
Net Cash/Debt	$27M	$95M
Current Ratio (TTM)	2.94x	7.48x
Quick Ratio (TTM)	1.91x	7.19x
Debt/Equity (TTM)	0.00x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.05	0.74
52W Performance	8.2%	-31.0%
YTD Performance	59.8%	4.4%
% from 52W High	-12.9%	-35.9%
% from 52W Low	73.7%	26.0%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.01x
FCF Yield (TTM)	3.4%	-37.9%
Earnings Yield (TTM)	8.5%	-74.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	39.7	-5,343.1
EV/GP/RG	N/A	N/A
Ticker research	View PLX research	View RNAC research

Valuation

P/E Ratio

PLX

12.11x

P/S Ratio

PLX

2.78x

RNAC

140.34x

EV/FCF

RNAC

-1.43x

PLX

25.63x

Growth & revenue

Revenue Growth TTM

PLX

30.1%

RNAC

-20.7%

Forward Revenue Growth

RNAC

-14.0%

PLX

-19.1%

Profitability & performance

Gross Margin

PLX

69.2%

RNAC

0.0%

ROE

PLX

31.6%

RNAC

-321582.0%

FCF Yield %

PLX

3.4%

RNAC

-37.9%

52-Week Performance

PLX

8.2%

RNAC

-31.0%

Detailed metrics comparison

PLX

Protalix Biotherapeutics Inc

RNAC

Cartesian Therapeutics Inc

Market Cap

PLX$224M

RNAC$207M

Enterprise Value

PLX$197M

RNAC$113M

Price

PLX$2.78

RNAC$7.06

P/E Ratio

PLX12.11x

RNACN/A

P/S Ratio

PLX2.78x

RNAC140.34x

EV/Sales

PLX2.44x

RNAC76.18x

EV/EBITDA

PLX7.37x

RNAC0.00x

P/B Ratio

PLX3.06x

RNAC296.12x

P/FCF Ratio

PLX29.21x

RNACN/A

EV/FCF

PLX25.63x

RNAC-1.43x

PEG Ratio

PLX0.06x

RNACN/A

Forward P/E (NTM)

PLXN/A

RNACN/A

Forward P/S (NTM)

PLX3.56x

RNAC473.62x

Revenue (TTM)

PLX$81M

RNAC$1M

Revenue Growth (YoY)

PLX30.1%

RNAC-20.7%

Forward Rev Growth

PLX-19.1%

RNAC-14.0%

Gross Margin (TTM)

PLX69.2%

RNAC0.0%

Operating Margin (TTM)

PLX28.9%

RNAC0.0%

EBITDA Margin (TTM)

PLX30.8%

RNAC-6503.1%

Net Margin (TTM)

PLX23.5%

RNAC-10422.5%

FCF Margin (TTM)

PLX9.5%

RNAC-5322.4%

Net Income (TTM)

PLX$19M

RNAC$-154M

FCF (TTM)

PLX$8M

RNAC$-79M

EPS (TTM)

PLX$0.23

RNAC-$5.16

ROE (TTM)

PLX31.6%

RNAC-321582.0%

ROA (TTM)

PLX20.1%

RNAC-4761.0%

ROIC (TTM)

PLX31.6%

RNAC-321582.0%

Cash

PLX$27M

RNAC$148M

Debt

PLX$0

RNAC$53M

Net Cash/Debt

PLX$27M

RNAC$95M

Current Ratio (TTM)

PLX2.94x

RNAC7.48x

Quick Ratio (TTM)

PLX1.91x

RNAC7.19x

Debt/Equity (TTM)

PLX0.00x

RNAC0.28x

Debt/Assets (TTM)

PLX0.0%

RNAC0.0%

Interest Coverage (TTM)

PLXN/A

RNACN/A

Net Debt/EBITDA (TTM)

PLX0.00x

RNAC0.00x

Beta

PLX-0.05

RNAC0.74

52W Performance

PLX8.2%

RNAC-31.0%

YTD Performance

PLX59.8%

RNAC4.4%

% from 52W High

PLX-12.9%

RNAC-35.9%

% from 52W Low

PLX73.7%

RNAC26.0%

Asset Turnover (TTM)

PLX0.85x

RNAC0.01x

FCF Yield (TTM)

PLX3.4%

RNAC-37.9%

Earnings Yield (TTM)

PLX8.5%

RNAC-74.3%

Dividend Yield (TTM)

PLXN/A

RNACN/A

Rule of 40

PLX39.7

RNAC-5,343.1

EV/GP/RG

PLXN/A

RNACN/A

Ticker research

View PLX research View RNAC research

Metric	PLX Protalix Biotherapeutics Inc	RNAC Cartesian Therapeutics Inc
Market & Valuation
Market Cap	$224M	$207M
Enterprise Value	$197M	$113M
Price	$2.78	$7.06
P/E Ratio	12.11x	N/A
P/S Ratio	2.78x	140.34x
EV/Sales	2.44x	76.18x
EV/EBITDA	7.37x	0.00x
P/B Ratio	3.06x	296.12x
P/FCF Ratio	29.21x	N/A
EV/FCF	25.63x	-1.43x
PEG Ratio	0.06x	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.56x	473.62x
Revenue & Growth
Revenue (TTM)	$81M	$1M
Revenue Growth (YoY)	30.1%	-20.7%
Forward Rev Growth	-19.1%	-14.0%
Profitability
Gross Margin (TTM)	69.2%	0.0%
Operating Margin (TTM)	28.9%	0.0%
EBITDA Margin (TTM)	30.8%	-6503.1%
Net Margin (TTM)	23.5%	-10422.5%
FCF Margin (TTM)	9.5%	-5322.4%
Net Income (TTM)	$19M	$-154M
FCF (TTM)	$8M	$-79M
EPS (TTM)	$0.23	-$5.16
ROE (TTM)	31.6%	-321582.0%
ROA (TTM)	20.1%	-4761.0%
ROIC (TTM)	31.6%	-321582.0%
Financial Health
Cash	$27M	$148M
Debt	$0	$53M
Net Cash/Debt	$27M	$95M
Current Ratio (TTM)	2.94x	7.48x
Quick Ratio (TTM)	1.91x	7.19x
Debt/Equity (TTM)	0.00x	0.28x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.05	0.74
52W Performance	8.2%	-31.0%
YTD Performance	59.8%	4.4%
% from 52W High	-12.9%	-35.9%
% from 52W Low	73.7%	26.0%
Efficiency & Yields
Asset Turnover (TTM)	0.85x	0.01x
FCF Yield (TTM)	3.4%	-37.9%
Earnings Yield (TTM)	8.5%	-74.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	39.7	-5,343.1
EV/GP/RG	N/A	N/A
Ticker research	View PLX research	View RNAC research